Cardiology
Applied Evidence
Obesity: When to consider surgery
Bariatric surgery is underutilized despite an obesity epidemic. Here, 3 patients pursue a surgical option when they can't reach their target...
From the Journals
Swings in four metabolic measures predicted death in healthy people
Risk for death is higher in people with swings in fasting blood glucose and cholesterol levels, systolic blood pressure, and body mass index.
Conference Coverage
Home telemonitoring for heart failure cuts mortality
MUNICH – Large, national German TIM-HF2 trial also shows fewer hospitalizations than with usual care.
From the Journals
ASPREE: What to do now about aspirin for healthy elderly people
While low-risk people don’t benefit, patients who are at mid to high cardiovascular risk clearly might.
Conference Coverage
Antithrombotic strategy 1 year after stenting in AF patients leans toward oral anticoagulant alone
SAN DIEGO – A primary endpoint failed to show noninferiority of oral anticoagulants alone versus anticoagulants plus antiplatelet therapy, but a...
Video
Get on top of home BP monitoring now
CHICAGO – The devices are good, available, and inexpensive, so what’s the holdup?
From the Journals
Under new ACC-AHA criteria, more pregnant women at risk of hypertension, adverse outcomes
The adverse outcomes – preeclampsia, gestational diabetes, and preterm birth – appeared to be mitigated by low-dose aspirin therapy.
Daily News Podcast
Does America have a gabapentinoid problem?
And atrial fibrillation guidelines may miss the mark with oral anticoagulation.
From the Journals
ICYMI: Wearable cardioverter-defibrillator ineffective at reducing arrhythmic death risk
Patients with a recent MI and an ejection fraction of 35% who wore the defibrillator experienced arrhythmic mortality similar to those who did not...
From the Journals
Atrial fib guidelines may fall short on oral anticoagulation
Oral anticoagulation threshold according to CHA2DS2-VASc score varied widely after accounting for varying stroke rates in published studies.
Conference Coverage
Rivaroxaban bonus: Early unmasking of occult GI cancers
MUNICH – Secondary analysis of COMPASS trial hits pay dirt.